Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation

Journal of Clinical Investigation

Volumn 124, Issue 12, 2014, Pages 5385-5397

  Sassi, Yassine ^a   Ahles, Andrea ^a   Truong, Dong Jiunn Jeffery ^a   Baqi, Younis ^b   Lee, Sang Yong ^b   Husse, Britta ^c   Hulot, Jean Sébastien ^d,e   Foinquinos, Ariana ^f   Thum, Thomas ^f,g   Müller, Christa E ^b   Dendorfer, Andreas ^c,h   Laggerbauer, Bernhard ^a   Engelhardt, Stefan ^a,h  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d SORBONNE UNIVERSITÉ   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; CYCLIC AMP; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; ABCC4 PROTEIN, MOUSE; ABCC4 PROTEIN, RAT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROBLAST; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIMARY CELL; ANIMAL; CARDIOMEGALY; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; RAT; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOMEGALY; CYCLIC AMP; FIBROBLASTS; HUMANS; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; RECEPTORS, ADENOSINE A2; SIGNAL TRANSDUCTION;

EID: 84915820638     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74349     Document Type: Article

References (50)

1. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac β-adrenergic receptors, and heart failure. Circulation. 2000;101(14):1634-1637.
2. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93(10):896-906.
3. Choi DJ, Rockman HA. β-Adrenergic receptor desensitization in cardiac hypertrophy and heart failure. Cell Biochem Biophys. 1999;31(3):321-329.
4. Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13(3):595-603.
5. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001;276(36):33747-33754.
6. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000;275(39):30069-30074.
7. Guo Y, et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl) adenine. J Biol Chem. 2003;278(32):29509-29514.
8. Ahloulay M, Déchaux M, Hassler C, Bouby N, Bankir L. Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J Clin Invest. 1996;98(10):2251-2258.
9. McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther. 2012;17(1):21-33.
10. Jackson EK, Raghvendra DK. The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu Rev Physiol. 2004;66:571-599.
11. Sassi Y, et al. Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J. 2012;26(3):1009-1017.
12. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension. 2001;37(4):1095-1100.
13. Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ectonucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta. 2003;1638(1):1-19.
14. Koszalka P, et al. Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res. 2004;95(8):814-821.
15. Xu X, et al. Ecto-5′-nucleotidase deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction. Hypertension. 2008;51(6):1557-1564.
16. Eckle T, et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007;115(12):1581-1590.
17. Weyler S, et al. Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem. 2006;1(8):891-902.
18. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808(5):1290-1308.
19. Epperson SA, Brunton LL, Ramirez-Sanchez I, Villarreal F. Adenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts. Am J Physiol Cell Physiol. 2009;296(5):C1171-C1177.
20. Rohrer D, Chruscinski A, Schauble E, Bernstein D, Kobilka B. Cardiovascular and metabolic alterations in mice lacking both β1- and β2-adrenergic receptors. J Biol Chem. 1999;274(24):16701-16708.
21. Bera T, Lee S, Salvatore G, Lee B, Pastan I. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med. 2001;7(8):509-516.
22. Brandenburger M, et al. Organotypic slice culture from human adult ventricular myocardium. Cardiovasc Res. 2012;93(1):50-59.
23. Liao Y, et al. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res. 2003;93(8):759-766.
24. Marienfeld U, Walter U, Simm A. Inhibition of rat cardiac fibroblast growth by cAMP - but not by cGMP-dependent protein kinase. Basic Res Cardiol. 2001;96(2):184-191.
25. Brundege J, Diao L, Proctor W, Dunwiddie T. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology. 1997;36(9):1201-1210.
26. Chiavegatti T, Costa V Jr, Araujo M, Godinho R. Skeletal muscle expresses the extracellular cyclic AMP - adenosine pathway. Br J Pharmacol. 2008;153(6):1331-1340.
27. Carey GB, Wotjukiewicz LJ, Goodman JM, Reineck KE, Overman KC. Extracellular cyclic AMP and adenosine appearance in adipose tissue of sus scrofa: effects of exercise. Exp Biol Med. 2004;229(10):1026-1032.
28. Corriden R, Insel P. Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci Signal. 2010;3(104):re1.
29. Sager G. Cyclic GMP transporters. Neurochem Int. 2004;45(6):865-873.
30. Gödecke S, Stumpe T, Schiller H, Schnittler HJ, Schrader J. Do rat cardiac myocytes release ATP on contraction? Am J Physiol Cell Physiol. 2005;289(3):C609-C616.
31. Lu D, Insel PA. Hydrolysis of extracellular ATP by ectonucleoside triphosphate diphosphohydrolase (ENTPD) establishes the set point for fibrotic activity of cardiac fibroblasts. J Biol Chem. 2013;288(26):19040-19049.
32. Toufektsian M, et al. Stimulation of A2A-adenosine receptors after myocardial infarction suppresses inflammatory activation and attenuates contractile dysfunction in the remote left ventricle. Am J Physiol Heart Circ Physiol. 2006;290(4):H1410-H1418.
33. Yang D, et al. The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci U S A. 2008;105(2):792-796.
34. Wakeno M, et al. Long-term stimulation of adenosine A2b receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation. 2006;114(18):1923-1932.
35. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol Med. 2013;19(6):345-354.
36. Meyer TE, et al. Antiadrenergic effects of adenosine in pressure overload hypertrophy. Hypertension. 2001;37(3):862-868.
37. Yang Z, et al. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol. 2002;282(3):H949-H955.
38. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Cardiac fibroblasts express the cAMP-adenosine pathway. Hypertension. 2000;36(3):337-342.
39. Jacobson K, Gao Z. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247-264.
40. Hofer AM, Lefkimmiatis K. Extracellular calcium and cAMP: second messengers as "third messengers"? Physiology (Bethesda, Md). 2007;22:320-327.
41. Muller C. General synthesis and properties of 1-monosubstituted xanthines. Synthesis. 1993;1:125-128.
42. Sauer R, et al. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem. 2000;43(3):440-448.
43. Hockemeyer J, Burbiel JC, Muller CE. Multi-gram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for parkinson's disease. J Org Chem. 2004;69(10):3308-3318.
44. Rockman HA, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991;88(18):8277-8281.
45. Leggas M, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol. 2004;24(17):7612-7621.
46. De Wolf CJF, et al. cGMP transport by vesicles from human and mouse erythrocytes. FEBS J. 2007;274(2):439-450.
47. Frost RJA, Engelhardt S. A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation. 2007;116(16):1768-1775.
48. Jentzsch C, et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol. 2012;52(1):13-20.
49. Bang C, et al. Cardiac fibroblast - derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014;124(5):2136-2146.
50. Nikolaev VO, Bünemann M, Hein L, Hannawacker A, Lohse MJ. Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem. 2004;279(36):37215-37218.